Loading…

A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail

Gastric cancer (GC) is a common high-mortality disease, causing a serious social burden. Traditional Chinese medicine has been utilized to prevent and treat GC for many years but its effects remain unclear. The aim of our study is to elucidate the anti-tumor effects and the possible mechanism of Jia...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2020-04, Vol.99 (16), p.e19757-e19757
Main Authors: Pan, Xiaoting, Tao, Heyun, Nie, Mengjun, Liu, Yuanjie, Huang, Pan, Liu, Shenlin, Sun, Wei, Wu, Jian, Ma, Ting, Dai, Anwei, Lu, Jianwei, Liu, Baorui, Zou, Xi, Sun, Qingmin
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c3550-d7eeaf2dd6dc13cc895ad3b18dc18cb6205e867f7b6f534f6ffefe11b92707573
container_end_page e19757
container_issue 16
container_start_page e19757
container_title Medicine (Baltimore)
container_volume 99
creator Pan, Xiaoting
Tao, Heyun
Nie, Mengjun
Liu, Yuanjie
Huang, Pan
Liu, Shenlin
Sun, Wei
Wu, Jian
Ma, Ting
Dai, Anwei
Lu, Jianwei
Liu, Baorui
Zou, Xi
Sun, Qingmin
description Gastric cancer (GC) is a common high-mortality disease, causing a serious social burden. Traditional Chinese medicine has been utilized to prevent and treat GC for many years but its effects remain unclear. The aim of our study is to elucidate the anti-tumor effects and the possible mechanism of Jianpi Yangzheng Xiaozheng decoction. This is a prospective, multicenter, randomized controlled trial continuing 1.5 years. Two hundred ten eligible patients will be randomly divided into 2 groups, the chemotherapy alone and the chemotherapy combined with JPYZXZ group at a ratio of 1:2. All patients will receive the treatment for 24 weeks and follow up for 1.5 years. The primary outcomes are one-year survival rate, progression-free survival, and overall survival (OS), while the secondary outcomes are immune related hematology test, objective response rate, tumor makers, traditional Chinese medicine syndrome points, fatigue scale, and quality of life scale. All of these outcomes will be analyzed at the end of the trail. This study will provide the objective evidence for the efficacy and safety of Jianpi Yangzheng Xiaozheng decoction in advanced GC. Furthermore, it will be helpful to form a therapeutic regimen in advanced GC by the combination of traditional medicine and western medicine.Trail registration: ChiCTR1900028147.
doi_str_mv 10.1097/MD.0000000000019757
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7220101</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2393054518</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3550-d7eeaf2dd6dc13cc895ad3b18dc18cb6205e867f7b6f534f6ffefe11b92707573</originalsourceid><addsrcrecordid>eNpdUsuOFCEUJUbjjK1fYGJYupgaeRRFlwuTTo-vZCZudE0oHt0oBSVQPWn_1j-Rnm7HBxu4l3POvRwuAM8xusSo569uri7Rn4V7zvgDcI4Z7RrWd-1DcI4QYQ3veXsGnuT8tYIoJ-1jcEYJxZXQnYOfK6i8C05JD3OZ9R5GC0uS2hUXQ02uty6YbOBotFP1CKcUfQwbFzawbA3Mc9q5XQVWntQ7GZTRcCNzSU5BdQgTnGRxJpQMhz1MZjP7Gp_obhznEPM8Tcnk7HYGKuM9nOJ0h4rhNVydGquFS1TRQxsTlHCcfXGqypp0AZMMOo7uR62tYii1RV-P9R3OPwWPrPTZPDvtC_Dl3dvP6w_N9af3H9er60ZRxlCjuTHSEq07rTBVatkzqemAlzVcqqEjiJllxy0fOstoaztrjTUYDz3hqFpPF-DNUXeah2rWobMkvZiSG2Xaiyid-PcmuK3YxJ3ghCBcv2YBXp4EUvw-m1zE6PLBDRlMnLMgtKeItQwvK5QeoSrFnJOx92UwEofhEDdX4v_hqKwXf3d4z_k9DRXQHgG30Vdb8zc_35oktkb6sr3TY7wnDUEEoRZz1NRMh-gvalbN4A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2393054518</pqid></control><display><type>article</type><title>A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail</title><source>PubMed Central (Open Access)</source><source>HEAL-Link subscriptions: Lippincott Williams &amp; Wilkins</source><source>IngentaConnect Journals</source><creator>Pan, Xiaoting ; Tao, Heyun ; Nie, Mengjun ; Liu, Yuanjie ; Huang, Pan ; Liu, Shenlin ; Sun, Wei ; Wu, Jian ; Ma, Ting ; Dai, Anwei ; Lu, Jianwei ; Liu, Baorui ; Zou, Xi ; Sun, Qingmin</creator><creatorcontrib>Pan, Xiaoting ; Tao, Heyun ; Nie, Mengjun ; Liu, Yuanjie ; Huang, Pan ; Liu, Shenlin ; Sun, Wei ; Wu, Jian ; Ma, Ting ; Dai, Anwei ; Lu, Jianwei ; Liu, Baorui ; Zou, Xi ; Sun, Qingmin</creatorcontrib><description>Gastric cancer (GC) is a common high-mortality disease, causing a serious social burden. Traditional Chinese medicine has been utilized to prevent and treat GC for many years but its effects remain unclear. The aim of our study is to elucidate the anti-tumor effects and the possible mechanism of Jianpi Yangzheng Xiaozheng decoction. This is a prospective, multicenter, randomized controlled trial continuing 1.5 years. Two hundred ten eligible patients will be randomly divided into 2 groups, the chemotherapy alone and the chemotherapy combined with JPYZXZ group at a ratio of 1:2. All patients will receive the treatment for 24 weeks and follow up for 1.5 years. The primary outcomes are one-year survival rate, progression-free survival, and overall survival (OS), while the secondary outcomes are immune related hematology test, objective response rate, tumor makers, traditional Chinese medicine syndrome points, fatigue scale, and quality of life scale. All of these outcomes will be analyzed at the end of the trail. This study will provide the objective evidence for the efficacy and safety of Jianpi Yangzheng Xiaozheng decoction in advanced GC. Furthermore, it will be helpful to form a therapeutic regimen in advanced GC by the combination of traditional medicine and western medicine.Trail registration: ChiCTR1900028147.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000019757</identifier><identifier>PMID: 32311976</identifier><language>eng</language><publisher>United States: the Author(s). Published by Wolters Kluwer Health, Inc</publisher><subject>Drugs, Chinese Herbal - pharmacology ; Drugs, Chinese Herbal - therapeutic use ; Humans ; Medicine, Chinese Traditional ; Multicenter Studies as Topic ; Phytotherapy ; Randomized Controlled Trials as Topic ; Stomach Neoplasms - drug therapy ; Stomach Neoplasms - immunology ; Stomach Neoplasms - mortality ; Study Protocol Clinical Trial</subject><ispartof>Medicine (Baltimore), 2020-04, Vol.99 (16), p.e19757-e19757</ispartof><rights>the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3550-d7eeaf2dd6dc13cc895ad3b18dc18cb6205e867f7b6f534f6ffefe11b92707573</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220101/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220101/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32311976$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pan, Xiaoting</creatorcontrib><creatorcontrib>Tao, Heyun</creatorcontrib><creatorcontrib>Nie, Mengjun</creatorcontrib><creatorcontrib>Liu, Yuanjie</creatorcontrib><creatorcontrib>Huang, Pan</creatorcontrib><creatorcontrib>Liu, Shenlin</creatorcontrib><creatorcontrib>Sun, Wei</creatorcontrib><creatorcontrib>Wu, Jian</creatorcontrib><creatorcontrib>Ma, Ting</creatorcontrib><creatorcontrib>Dai, Anwei</creatorcontrib><creatorcontrib>Lu, Jianwei</creatorcontrib><creatorcontrib>Liu, Baorui</creatorcontrib><creatorcontrib>Zou, Xi</creatorcontrib><creatorcontrib>Sun, Qingmin</creatorcontrib><title>A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Gastric cancer (GC) is a common high-mortality disease, causing a serious social burden. Traditional Chinese medicine has been utilized to prevent and treat GC for many years but its effects remain unclear. The aim of our study is to elucidate the anti-tumor effects and the possible mechanism of Jianpi Yangzheng Xiaozheng decoction. This is a prospective, multicenter, randomized controlled trial continuing 1.5 years. Two hundred ten eligible patients will be randomly divided into 2 groups, the chemotherapy alone and the chemotherapy combined with JPYZXZ group at a ratio of 1:2. All patients will receive the treatment for 24 weeks and follow up for 1.5 years. The primary outcomes are one-year survival rate, progression-free survival, and overall survival (OS), while the secondary outcomes are immune related hematology test, objective response rate, tumor makers, traditional Chinese medicine syndrome points, fatigue scale, and quality of life scale. All of these outcomes will be analyzed at the end of the trail. This study will provide the objective evidence for the efficacy and safety of Jianpi Yangzheng Xiaozheng decoction in advanced GC. Furthermore, it will be helpful to form a therapeutic regimen in advanced GC by the combination of traditional medicine and western medicine.Trail registration: ChiCTR1900028147.</description><subject>Drugs, Chinese Herbal - pharmacology</subject><subject>Drugs, Chinese Herbal - therapeutic use</subject><subject>Humans</subject><subject>Medicine, Chinese Traditional</subject><subject>Multicenter Studies as Topic</subject><subject>Phytotherapy</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Stomach Neoplasms - drug therapy</subject><subject>Stomach Neoplasms - immunology</subject><subject>Stomach Neoplasms - mortality</subject><subject>Study Protocol Clinical Trial</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpdUsuOFCEUJUbjjK1fYGJYupgaeRRFlwuTTo-vZCZudE0oHt0oBSVQPWn_1j-Rnm7HBxu4l3POvRwuAM8xusSo569uri7Rn4V7zvgDcI4Z7RrWd-1DcI4QYQ3veXsGnuT8tYIoJ-1jcEYJxZXQnYOfK6i8C05JD3OZ9R5GC0uS2hUXQ02uty6YbOBotFP1CKcUfQwbFzawbA3Mc9q5XQVWntQ7GZTRcCNzSU5BdQgTnGRxJpQMhz1MZjP7Gp_obhznEPM8Tcnk7HYGKuM9nOJ0h4rhNVydGquFS1TRQxsTlHCcfXGqypp0AZMMOo7uR62tYii1RV-P9R3OPwWPrPTZPDvtC_Dl3dvP6w_N9af3H9er60ZRxlCjuTHSEq07rTBVatkzqemAlzVcqqEjiJllxy0fOstoaztrjTUYDz3hqFpPF-DNUXeah2rWobMkvZiSG2Xaiyid-PcmuK3YxJ3ghCBcv2YBXp4EUvw-m1zE6PLBDRlMnLMgtKeItQwvK5QeoSrFnJOx92UwEofhEDdX4v_hqKwXf3d4z_k9DRXQHgG30Vdb8zc_35oktkb6sr3TY7wnDUEEoRZz1NRMh-gvalbN4A</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Pan, Xiaoting</creator><creator>Tao, Heyun</creator><creator>Nie, Mengjun</creator><creator>Liu, Yuanjie</creator><creator>Huang, Pan</creator><creator>Liu, Shenlin</creator><creator>Sun, Wei</creator><creator>Wu, Jian</creator><creator>Ma, Ting</creator><creator>Dai, Anwei</creator><creator>Lu, Jianwei</creator><creator>Liu, Baorui</creator><creator>Zou, Xi</creator><creator>Sun, Qingmin</creator><general>the Author(s). Published by Wolters Kluwer Health, Inc</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200401</creationdate><title>A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail</title><author>Pan, Xiaoting ; Tao, Heyun ; Nie, Mengjun ; Liu, Yuanjie ; Huang, Pan ; Liu, Shenlin ; Sun, Wei ; Wu, Jian ; Ma, Ting ; Dai, Anwei ; Lu, Jianwei ; Liu, Baorui ; Zou, Xi ; Sun, Qingmin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3550-d7eeaf2dd6dc13cc895ad3b18dc18cb6205e867f7b6f534f6ffefe11b92707573</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Drugs, Chinese Herbal - pharmacology</topic><topic>Drugs, Chinese Herbal - therapeutic use</topic><topic>Humans</topic><topic>Medicine, Chinese Traditional</topic><topic>Multicenter Studies as Topic</topic><topic>Phytotherapy</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Stomach Neoplasms - drug therapy</topic><topic>Stomach Neoplasms - immunology</topic><topic>Stomach Neoplasms - mortality</topic><topic>Study Protocol Clinical Trial</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pan, Xiaoting</creatorcontrib><creatorcontrib>Tao, Heyun</creatorcontrib><creatorcontrib>Nie, Mengjun</creatorcontrib><creatorcontrib>Liu, Yuanjie</creatorcontrib><creatorcontrib>Huang, Pan</creatorcontrib><creatorcontrib>Liu, Shenlin</creatorcontrib><creatorcontrib>Sun, Wei</creatorcontrib><creatorcontrib>Wu, Jian</creatorcontrib><creatorcontrib>Ma, Ting</creatorcontrib><creatorcontrib>Dai, Anwei</creatorcontrib><creatorcontrib>Lu, Jianwei</creatorcontrib><creatorcontrib>Liu, Baorui</creatorcontrib><creatorcontrib>Zou, Xi</creatorcontrib><creatorcontrib>Sun, Qingmin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pan, Xiaoting</au><au>Tao, Heyun</au><au>Nie, Mengjun</au><au>Liu, Yuanjie</au><au>Huang, Pan</au><au>Liu, Shenlin</au><au>Sun, Wei</au><au>Wu, Jian</au><au>Ma, Ting</au><au>Dai, Anwei</au><au>Lu, Jianwei</au><au>Liu, Baorui</au><au>Zou, Xi</au><au>Sun, Qingmin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>99</volume><issue>16</issue><spage>e19757</spage><epage>e19757</epage><pages>e19757-e19757</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Gastric cancer (GC) is a common high-mortality disease, causing a serious social burden. Traditional Chinese medicine has been utilized to prevent and treat GC for many years but its effects remain unclear. The aim of our study is to elucidate the anti-tumor effects and the possible mechanism of Jianpi Yangzheng Xiaozheng decoction. This is a prospective, multicenter, randomized controlled trial continuing 1.5 years. Two hundred ten eligible patients will be randomly divided into 2 groups, the chemotherapy alone and the chemotherapy combined with JPYZXZ group at a ratio of 1:2. All patients will receive the treatment for 24 weeks and follow up for 1.5 years. The primary outcomes are one-year survival rate, progression-free survival, and overall survival (OS), while the secondary outcomes are immune related hematology test, objective response rate, tumor makers, traditional Chinese medicine syndrome points, fatigue scale, and quality of life scale. All of these outcomes will be analyzed at the end of the trail. This study will provide the objective evidence for the efficacy and safety of Jianpi Yangzheng Xiaozheng decoction in advanced GC. Furthermore, it will be helpful to form a therapeutic regimen in advanced GC by the combination of traditional medicine and western medicine.Trail registration: ChiCTR1900028147.</abstract><cop>United States</cop><pub>the Author(s). Published by Wolters Kluwer Health, Inc</pub><pmid>32311976</pmid><doi>10.1097/MD.0000000000019757</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2020-04, Vol.99 (16), p.e19757-e19757
issn 0025-7974
1536-5964
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7220101
source PubMed Central (Open Access); HEAL-Link subscriptions: Lippincott Williams & Wilkins; IngentaConnect Journals
subjects Drugs, Chinese Herbal - pharmacology
Drugs, Chinese Herbal - therapeutic use
Humans
Medicine, Chinese Traditional
Multicenter Studies as Topic
Phytotherapy
Randomized Controlled Trials as Topic
Stomach Neoplasms - drug therapy
Stomach Neoplasms - immunology
Stomach Neoplasms - mortality
Study Protocol Clinical Trial
title A clinical study of traditional Chinese medicine prolonging the survival of advanced gastric cancer patients by regulating the immunosuppressive cell population: A study protocol for a multicenter, randomized controlled trail
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T13%3A27%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20clinical%20study%20of%20traditional%20Chinese%20medicine%20prolonging%20the%20survival%20of%20advanced%20gastric%20cancer%20patients%20by%20regulating%20the%20immunosuppressive%20cell%20population:%20A%20study%20protocol%20for%20a%20multicenter,%20randomized%20controlled%20trail&rft.jtitle=Medicine%20(Baltimore)&rft.au=Pan,%20Xiaoting&rft.date=2020-04-01&rft.volume=99&rft.issue=16&rft.spage=e19757&rft.epage=e19757&rft.pages=e19757-e19757&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000019757&rft_dat=%3Cproquest_pubme%3E2393054518%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3550-d7eeaf2dd6dc13cc895ad3b18dc18cb6205e867f7b6f534f6ffefe11b92707573%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2393054518&rft_id=info:pmid/32311976&rfr_iscdi=true